Heron Therapeutics Inc (NAS:HRTX)

$ 3.29 -0.13 (-3.8%) Market Cap: 495.65 Mil Enterprise Value: 622.88 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 68/100

Q1 2024 Heron Therapeutics Inc Earnings Call Transcript
May 07, 2024

$2.87 (+1.06%)

Earnings
Q4 2023 Heron Therapeutics Inc Earnings Call Transcript
Mar 12, 2024

$2.36 (-2.07%)

Earnings
Q3 2023 Heron Therapeutics Inc Earnings Call Transcript
Nov 14, 2023

$0.54 (-1.06%)

Earnings
Q2 2023 Heron Therapeutics Inc Earnings Call Transcript
Aug 14, 2023

$1.51 (-6.79%)

Earnings
Q1 2023 Heron Therapeutics Inc Earnings Call Transcript
May 11, 2023

$2.23 (-8.98%)

Earnings
Heron Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 20, 2023
Q4 2022 Heron Therapeutics Inc Earnings Call Transcript
Mar 23, 2023

$2.07 (+4.82%)

Earnings
Q3 2022 Heron Therapeutics Inc Earnings Call Transcript
Nov 08, 2022

$3.45 (+0.88%)

Earnings
Heron Therapeutics Inc Investor Call Transcript
Sep 19, 2022
Q2 2022 Heron Therapeutics Inc Earnings Call Transcript
Aug 09, 2022

$4.11 (+15.13%)

Earnings
Q1 2022 Heron Therapeutics Inc Earnings Call Transcript
May 09, 2022

$3.61 (-12.17%)

Earnings
Heron Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 11, 2022
Q4 2021 Heron Therapeutics Inc Earnings Call Transcript
Feb 28, 2022

$7.1 (-5.96%)

Earnings
Heron Therapeutics Inc Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF Transcript
Dec 09, 2021
Q3 2021 Heron Therapeutics Inc Earnings Call Transcript
Nov 03, 2021

$11.29 (-1.14%)

Earnings
Heron Therapeutics Inc to Host U.S. FDA Approval of ZYNRELEF™ - Conference Call Transcript
May 13, 2021
Heron Therapeutics Inc 2020 Conference Call Transcript
Jun 29, 2020
Heron Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 17, 2020
Heron Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Oct 02, 2019
Heron Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference Transcript
May 14, 2019
Heron Therapeutics Inc to discuss the Complete Response Letter - Conference Call Transcript
May 01, 2019

Q1 2022 Heron Therapeutics Inc Earnings Call Transcript

May 09, 2022 / 08:30PM GMT

Release Date Price: $3.61 (-12.17%)

Transcript 10-Q8-K

Operator

Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Heron Therapeutics First Quarter 2022 Earnings Conference. As a reminder, this conference is being recorded. Now I would like to turn the call over to David Szekeres, Executive Vice President, Chief Operating Officer. Please proceed.

David L. Szekeres

Heron Therapeutics, Inc. - Executive VP & COO

Thank you, Jason. Good afternoon, everyone, and thank you for joining us. With me today from Heron are Barry Quart, Chief Executive Officer and Chairman; John Poyhonen, President and Chief Commercial Officer; and Kimberly Manhard, Executive Vice President of Drug Development and Board Director. For those of you participating via conference call, the slides are made available via webcast and can also be accessed by going to the Investor Relations page of our website following conclusion of today's call.

Before we begin, I would like to remind you that this call will contain forward-looking statements concerning Heron's future expectations, plans, prospects, corporate strategy and

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.